EA201100293A1 - Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции - Google Patents

Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции

Info

Publication number
EA201100293A1
EA201100293A1 EA201100293A EA201100293A EA201100293A1 EA 201100293 A1 EA201100293 A1 EA 201100293A1 EA 201100293 A EA201100293 A EA 201100293A EA 201100293 A EA201100293 A EA 201100293A EA 201100293 A1 EA201100293 A1 EA 201100293A1
Authority
EA
Eurasian Patent Office
Prior art keywords
options
treatment
symptoms
prevention
combinations
Prior art date
Application number
EA201100293A
Other languages
English (en)
Russian (ru)
Inventor
Теренс К. Дал
Марк М. Меннинг
Реза Олияй
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201100293A1 publication Critical patent/EA201100293A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201100293A 2003-01-14 2004-01-13 Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции EA201100293A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44024603P 2003-01-14 2003-01-14
US44030803P 2003-01-14 2003-01-14

Publications (1)

Publication Number Publication Date
EA201100293A1 true EA201100293A1 (ru) 2011-08-30

Family

ID=32776014

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200501134A EA015145B1 (ru) 2003-01-14 2004-01-13 Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
EA201100293A EA201100293A1 (ru) 2003-01-14 2004-01-13 Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200501134A EA015145B1 (ru) 2003-01-14 2004-01-13 Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции

Country Status (26)

Country Link
US (11) US20060234982A1 (fr)
EP (4) EP1923063A3 (fr)
JP (8) JP2006515624A (fr)
KR (3) KR20090053867A (fr)
CN (2) CN102670629B (fr)
AP (1) AP2089A (fr)
AT (1) ATE398455T1 (fr)
AU (3) AU2004206827A1 (fr)
BR (1) BRPI0406760A (fr)
CA (2) CA2512475C (fr)
CY (1) CY1108355T1 (fr)
DE (1) DE602004014470D1 (fr)
DK (1) DK1583542T3 (fr)
EA (2) EA015145B1 (fr)
ES (1) ES2308136T3 (fr)
HK (1) HK1079122A1 (fr)
HR (2) HRP20050619A2 (fr)
IL (1) IL169243A (fr)
IS (1) IS7977A (fr)
MX (1) MXPA05007016A (fr)
NO (3) NO337917B1 (fr)
NZ (1) NZ540728A (fr)
PL (2) PL378368A1 (fr)
PT (1) PT1583542E (fr)
SI (1) SI1583542T1 (fr)
WO (2) WO2004064846A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
EP3165220B1 (fr) 2004-12-03 2019-04-03 Merck Sharp & Dohme Corp. Composition pharmaceutique contenant un agent d'anti-nucléation
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
EP2049506B2 (fr) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
RU2470846C2 (ru) * 2007-01-20 2012-12-27 Мерк Патент Гмбх Повторно закрываемый контейнер для упаковки мягких капсул
WO2008096369A2 (fr) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Préparation pharmaceutique utilisable en thérapie anti-vih
US20100196273A1 (en) * 2007-02-12 2010-08-05 Board Of Regents, University Of Texas System Novel agent for in vivo pet imaging of tumor proliferation
PT2487163T (pt) 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
NZ584521A (en) * 2007-10-10 2011-03-31 Avantor Performance Mat Inc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CA2713423A1 (fr) 2008-01-18 2009-07-23 North Carolina State University Peptides et methodes d'utilisation comme agents therapeutiques et agents de criblage
EP3085377A1 (fr) 2008-01-25 2016-10-26 Chimerix, Inc. Méthodes de traitement d'infections virales
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (fr) 2008-12-23 2017-02-22 Gilead Pharmasset LLC Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
AU2010210598B2 (en) 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
ES2969969T3 (es) * 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
EP2389929A1 (fr) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations pharmaceutiques de Ténofovir
EP2579892A2 (fr) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
CN103038241B (zh) * 2010-08-01 2015-06-17 正大天晴药业集团股份有限公司 泰诺福韦双特戊酯富马酸盐的晶体
CN106511357A (zh) * 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
CA2856722C (fr) 2011-11-30 2022-11-22 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
CA2857490C (fr) 2011-12-22 2020-03-31 Geron Corporation Analogues de guanine en tant que substrats de telomerase et affecteurs de la longueur de telomeres
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CN104105484A (zh) 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9227990B2 (en) * 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
CN103127028A (zh) * 2013-03-14 2013-06-05 南京恒道医药科技有限公司 一种含有富马酸替诺福韦二吡呋酯的胶囊剂
NO2865735T3 (fr) 2013-07-12 2018-07-21
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
MX2016002560A (es) * 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CA2942877A1 (fr) 2014-04-08 2015-10-15 Nitzan SHAHAR Forme pharmaceutique unitaire comprenant de l'emtricitabine, du tenofovir, du darunavir et du ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
EP3273946A1 (fr) * 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Formulation pharmaceutique comprenant de la sembragiline
NZ735575A (en) 2015-04-02 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PT4070788T (pt) * 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3503895B1 (fr) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
WO2018118826A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Composés benzyl-amide phosphodiamide antiviraux
CN106749254B (zh) * 2017-01-10 2018-05-25 青岛科技大学 一种6-氨基嘌呤乙基萘乙酸酯类化合物及其作为植物生长调节剂的用途
WO2018153977A1 (fr) * 2017-02-24 2018-08-30 Hexal Ag Composition stable de ténofovir alafénamide
GB201705087D0 (en) * 2017-03-30 2017-05-17 Univ Liverpool Method for producing a liquid composition
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
KR102077060B1 (ko) * 2017-07-14 2020-02-13 주식회사 종근당 테노포비어 디소프록실 아스파르트산 염을 포함하는 약제학적 조성물
RU2666727C1 (ru) * 2017-07-18 2018-09-12 Андрей Александрович Иващенко Ингибитор вируса гепатита В (ВГВ)
TR201713954A2 (tr) 2017-09-20 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
CN110261631A (zh) * 2019-07-26 2019-09-20 重庆德方信息技术有限公司 用于健康检测装置的滴液机构
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113880898B (zh) * 2020-10-30 2023-07-25 杭州拉林智能科技有限公司 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568164A (en) 1896-09-22 Motor attachment for bicycles
CH389608A (de) 1960-01-19 1965-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Äthern
US3524846A (en) * 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4003878A (en) * 1972-12-07 1977-01-18 Avtex Fibers Inc. Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4384005A (en) 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
GB2111043B (en) 1980-12-12 1985-02-06 Ciba Geigy Ag Novel cephalosporin esters
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
JPS5879983A (ja) * 1981-11-06 1983-05-13 Kanebo Ltd 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
EP0141927B1 (fr) * 1983-08-18 1991-10-30 Beecham Group Plc Dérivés de guanine antiviraux
US5155268A (en) * 1984-05-04 1992-10-13 The Upjohn Company Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides
EP0182024B1 (fr) 1984-09-20 1991-04-03 Beecham Group Plc Dérivés de purine et leur utilisation pharmaceutique
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ222553A (en) 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
DE3790883T1 (fr) 1987-01-20 1988-12-08
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5453503A (en) 1988-10-11 1995-09-26 Eli Lilly And Company Azetidinone intermediates to carbacephalosporins and process
CA2001715C (fr) 1988-11-14 1999-12-28 Muzammil M. Mansuri Nucleosides et nucleotides carbocycliques
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1991019721A1 (fr) 1990-06-13 1991-12-26 Arnold Glazier Promedicaments phosphoreux
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
HU9300132D0 (en) 1990-07-19 1993-04-28 Beecham Group Plc Method for producing phosphono-alkene-purine derivatives and medical preparatives of anti-viral effect containing them
KR100221981B1 (ko) * 1990-08-10 1999-09-15 안토닌 포레이트 뉴클레오티드의 신규 제조방법
EP0481214B1 (fr) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
CA2054126A1 (fr) 1990-10-26 1992-04-27 Michiyuki Sendai Production et utilisation de composes de type cephem
US5587480A (en) 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5208221A (en) * 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
ATE173267T1 (de) 1992-06-23 1998-11-15 Yamanouchi Pharma Co Ltd Neues kristall von heterozyclischen bis(phosphonsäure) monohydrat-derivat
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5432172A (en) 1992-08-03 1995-07-11 The Research Foundation Of State University Of New York Biological applications of alkaloids derived from the tunicate Eudistoma sp.
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
NZ248852A (en) 1992-10-28 1997-06-24 Squibb & Sons Inc Alpha-phosphono and phosphinosulphonates and medicaments thereof
EP0684953A4 (fr) * 1993-02-03 1999-12-22 Gensia Inc Inhibiteurs d'adenosine-kinase comprenant des derives de lyxofuranosyle.
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2126601A1 (fr) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Derives d'ester phosphonate de nucleotide
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995007920A1 (fr) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Analogues de nucleotides
KR100386685B1 (ko) 1993-09-17 2003-12-31 길리애드 사이언시즈, 인코포레이티드 뉴클레오타이드동족체류
WO1995032957A1 (fr) 1994-05-27 1995-12-07 Astra Aktiebolag Nouveaux derives ethoxycarbonyloxymethyles de benzinidazoles substituees
US5514557A (en) 1994-06-06 1996-05-07 Genetic Testing Institute Inc. Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins
PE32296A1 (es) 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5512596A (en) * 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5486806A (en) * 1994-11-09 1996-01-23 Firari; Harold A. Anti-hijacking and theft prevention device for motor vehicles
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
JPH11507632A (ja) * 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US5618964A (en) * 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
CA2261619C (fr) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Analogues de nucleotides
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5733788A (en) 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
US6121315A (en) * 1996-09-20 2000-09-19 Warner-Lambert Company Oral compositions containing a zinc compound
GB9622681D0 (en) 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
DK1256584T3 (da) * 1997-07-25 2004-12-06 Gilead Sciences Inc Fremgangsmåde til fremstilling af adefovir-dipivoxil
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6270957B1 (en) * 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
CO4970782A1 (es) 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
EP1332757B1 (fr) 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Formulation de comprimé d' efavirenz
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
EP1535921A1 (fr) 1998-08-12 2005-06-01 Gilead Sciences, Inc. Procédé de préparation de 1,3-oxathiolanes nucléosides
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
DK1380303T3 (da) 1998-11-02 2008-12-01 Gilead Sciences Inc Kombinationsterapi til behandling af hepatitis B-virus
GB9909154D0 (en) 1999-04-22 1999-06-16 Nippon Glaxo Limited Pharmaceutical formulation
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
DE60114772T2 (de) 2000-02-02 2006-07-20 Dorian Bevec Aromatisches guanylhydrazon zur behandlung resistenter viraler infektionen
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba
CN1291994C (zh) * 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
JP2005500252A (ja) 2000-12-15 2005-01-06 トライアングル・フアーマシユーテイカルズ・インコーポレイテツド リバビリン又はマイコフェノール酸などのｉｍｄｐｈ阻害剤とｄａｐｄの併用療法
US6900315B2 (en) 2001-02-06 2005-05-31 Yale University 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
DK1389207T3 (da) 2001-03-01 2006-04-18 Gilead Sciences Inc Polymorfe og andre krystallinske former af cis-FTC
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030124186A1 (en) 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
PT2260833E (pt) 2002-01-16 2012-12-26 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e um diurético
CA2474056A1 (fr) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Therapie combinee pour le traitement d'infection vih
CN1656109A (zh) * 2002-04-26 2005-08-17 吉里德科学公司 非核苷逆转录酶抑制剂
CA2502625A1 (fr) 2002-12-09 2004-06-24 The University Of Georgia Research Foundation, Inc. Dioxolane thymine et combinaisons utilisables contre les souches resistantes du vih
MXPA05006954A (es) * 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
JP2006527184A (ja) * 2003-06-06 2006-11-30 エティファーム 口腔内分散性多層錠剤
CA2598607A1 (fr) 2005-01-18 2006-07-27 Adra N. Chaker Methodes et compositions utilisees pour reguler le cycle cellulaire
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2612788A1 (fr) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines et compositions pharmaceutiques destinees au traitement de l'hepatite c
US20070026441A1 (en) * 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients
US7448494B2 (en) * 2005-08-10 2008-11-11 Certain Teed Corporation Loose fill insulation packaged with additive
AP2008004533A0 (en) 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
GB0525898D0 (en) 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
AU2008206695A1 (en) 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
AU2009279604A1 (en) 2008-08-06 2010-02-11 Bionevia Pharmaceuticals, Inc. Flupirtine hydrochloride maleic acid cocrystal
WO2012003413A1 (fr) 2010-06-30 2012-01-05 The Broad Institute, Inc. Nouvelles formes solides de tacédinaline
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物

Also Published As

Publication number Publication date
CY1108355T1 (el) 2014-02-12
AU2004206821B2 (en) 2009-02-26
NO20150656A1 (no) 2005-10-13
EP1583542B1 (fr) 2008-06-18
JP2015098488A (ja) 2015-05-28
AU2004206827A1 (en) 2004-08-05
US20170273994A1 (en) 2017-09-28
US20150111855A1 (en) 2015-04-23
NO340951B1 (no) 2017-07-24
PT1583542E (pt) 2008-09-17
JP2021004264A (ja) 2021-01-14
EP1583542A1 (fr) 2005-10-12
US20040224917A1 (en) 2004-11-11
JP2014037430A (ja) 2014-02-27
DK1583542T3 (da) 2008-09-22
AP2005003348A0 (en) 2005-06-30
US20090143314A1 (en) 2009-06-04
IL169243A (en) 2008-12-29
NO20171193A1 (no) 2005-10-13
HK1079122A1 (en) 2006-03-31
WO2004064846A1 (fr) 2004-08-05
CN105596356A (zh) 2016-05-25
EP1583542B9 (fr) 2008-10-22
BRPI0406760A (pt) 2005-12-20
HRP20140379A2 (hr) 2014-07-18
KR20080032014A (ko) 2008-04-11
EP1923063A2 (fr) 2008-05-21
US20150111856A1 (en) 2015-04-23
EP1923063A3 (fr) 2009-04-08
HRP20050619A2 (en) 2005-10-31
US20060234982A1 (en) 2006-10-19
EP3025718A1 (fr) 2016-06-01
US20090036408A1 (en) 2009-02-05
EA200501134A1 (ru) 2005-12-29
ATE398455T1 (de) 2008-07-15
PL408254A1 (pl) 2014-07-21
WO2004064845A1 (fr) 2004-08-05
US20170232019A1 (en) 2017-08-17
KR100860136B1 (ko) 2008-09-25
SI1583542T1 (sl) 2008-12-31
AU2004206821A1 (en) 2004-08-05
AU2004206821C1 (en) 2009-10-01
JP2010120957A (ja) 2010-06-03
PL378368A1 (pl) 2006-04-03
NZ540728A (en) 2008-08-29
CN102670629A (zh) 2012-09-19
AU2009200414A1 (en) 2009-02-26
US20060246130A1 (en) 2006-11-02
CA2512475A1 (fr) 2004-08-05
US8592397B2 (en) 2013-11-26
WO2004064845A8 (fr) 2004-09-23
US9457036B2 (en) 2016-10-04
US8716264B2 (en) 2014-05-06
JP2006516570A (ja) 2006-07-06
IS7977A (is) 2005-08-12
US20140213556A1 (en) 2014-07-31
NO20053817D0 (no) 2005-08-12
DE602004014470D1 (de) 2008-07-31
AP2089A (en) 2010-01-11
US9744181B2 (en) 2017-08-29
CN102670629B (zh) 2016-02-24
JP4996241B2 (ja) 2012-08-08
ES2308136T3 (es) 2008-12-01
JP2006515624A (ja) 2006-06-01
CA2512319A1 (fr) 2004-08-05
CA2512475C (fr) 2009-06-02
NO20053817L (no) 2005-10-13
JP2019052174A (ja) 2019-04-04
EP1585527A1 (fr) 2005-10-19
KR20050092755A (ko) 2005-09-22
NO337917B1 (no) 2016-07-11
JP2017057232A (ja) 2017-03-23
AU2009200414B2 (en) 2011-12-08
MXPA05007016A (es) 2005-09-12
EA015145B1 (ru) 2011-06-30
KR20090053867A (ko) 2009-05-27
US20040224916A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
EA201100293A1 (ru) Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
CY1124914T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιεχουν αναστολεα ιντεγκρασης
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
MA31305B1 (fr) Administration hebdomadaire d'inhibiteurs de la dipeptidyle peptidase
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
CL2010000520A1 (es) Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c.
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
HRP20161680T1 (hr) Farmaceutski pripravak koji sadrži ne-nukleozidni inhibitor reverzne transkriptaze
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MY143795A (en) Tetrahydropyridoindole derivatives
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
EA201201265A1 (ru) Композиция (варианты), способ ее получения, резервуар, содержащий указанную композицию, и способ лечения вирусных заболеваний с ее использованием
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201370001A1 (ru) Противовирусные составы для местного применения
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MD3661373T2 (ro) Compoziție farmaceutică pentru tratamentul anemiei
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
MX2022000411A (es) Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona.
NZ601519A (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION comprising lamivudine and adefovir dipivoxil
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
AR101679A2 (es) Composiciones para el tratamiento antiviral combinado
AR043332A1 (es) Composiciones y metodos para terapia antiviral
EA200600176A1 (ru) Фармацевтические композиции, содержащие аскорбиновую кислоту для лечения грибковых суперинфекций и грибковых рецидивов